Home > Insider Trading > Filing (0001209191-15-020135)

Filing Details

Accession Number:: 0001209191-15-020135
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-03-02 12:22:23
Reporting Period:: 2015-02-26

Filing Date:: 2015-03-02
Accepted Time:: 2015-03-02 12:22:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1279695	Universal Biosensors Inc	UBI	Surgical & Medical Instruments & Apparatus (3841)	980424072

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1514822	Paul Wright	1 Corporate Avenue Rowville Victoria C3 3178	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-02-26	269,088	$99,812.57	606,516	No	4	P	Indirect	By Chatsworth Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Chatsworth Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	44,666	Indirect	By Macqarie Super Fund Manager
Common Stock	142,105	Indirect	By P K W Super Fund
Common Stock	2,957	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$0.00	2020-12-11	60,000	60,000	Direct
Common Stock	Stock Option (Right to Buy)	$0.00	2019-11-12	37,500	37,500	Direct
Common Stock	Stock Option (Right to Buy)	$1.38	2018-02-23	2,300,000	2,300,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2020-12-11	60,000	60,000	Direct
2019-11-12	37,500	37,500	Direct
2018-02-23	2,300,000	2,300,000	Direct

Footnotes

The prices reported are stated in Australian dollars.
The reported securities are held in trust for the benefit of the Reporting Person. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The reported securities are held by the Macquarie Super Fund Manager in a pooled superannuation fund for the account of the Reporting Person.
The reported securities are held by the Macquarie Super Fund Manager in trust and for the account of the Reporting Person.
On December 12, 2013, the board of directors approved the grant of these options subject to shareholder approval. Such shareholder approval was received on June 12, 2014. The stock options vest and become exercisable in three equal tranches om 12/31/14, 12/31/15 and 12/31/16.
On November 13, 2012, the board of directors approved the grant of these options subject to shareholder approval. Such shareholder approval was received on May 16, 2013. The stock options vest and become exercisable in three equal tranches om 12/31/13, 12/31/14 and 12/31/15.
1,400,000 options vest in equal traunches over three years subject to continued employment at the time of vesting. 500,000 of the options vested upon the company entering into a material partnership/licensing agreement with Siemens Healthcare Diagnostics, Inc. on September 9, 2011. 400,000 options vest upon CE marketing or first regulatory approval in the United States of the final test to which the partnership/licensing arranagement relates, subject to continued employment at the time of vesting.